^
Association details:
Biomarker:CDH1 deletion
Cancer:Breast Cancer
Drug:entinostat (SNDX-275) (HDAC inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors

Published date:
12/30/2021
Excerpt:
CDH1-/- breast and gastric cells were more sensitive to the pan-HDAC inhibitors entinostat, pracinostat, mocetinostat and vorinostat than wild-type cells, with an elevated growth inhibition that was, in part, attributable to increased apoptosis....Finally, entinostat enhanced Cdh1 expression in heterozygous Cdh1+/- murine organoids. In conclusion, entinostat is a promising drug for the chemoprevention and/or treatment of HDGC and may also be beneficial for the treatment of sporadic CDH1-deficient cancers.
DOI:
10.3390/cancers14010175